Brief Summary
The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advancedat a late stage, far along or metastatic Non-small Cell Lung Cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs (NSCLC) with homozygous MTAP deletion after progression on prior therapies.
Intervention / Treatment
- Drug: BMS-986504
Inclusion Criteria
- Histologically confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of NSCLC and homozygous MTAP deletion detected in tumor tissuea group of cells that work together to perform a function and willingness to provide archival/fresh samples at screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening for central MTAP status confirmation.
- Advanced or metastatic NSCLC not amenable to curative therapies after progression on prior therapies at the time of enrollment (based on the American Joint Committee on Cancer, Ninth Edition).
- At least 1 measurable lesion as per RECIST v1.1.
- Documented radiographic disease progression on or after the most recent line of treatment.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status of 0-1.
- Participant must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.
- Capability to swallow tablets intact (without chewing or crushing).